Healius (ASX:HLS) completes acquisition of Agilex Biolabs

Company News

by Lauren Evans

Healius (ASX:HLS) has completed the acquisition of all of the issued capital of bioanalytical firm Agilex Biolabs, which is valued at $301.3 million. 

Back in December, Healius said it viewed the deal as a long-term strategic acquisition that would provide the company with a platform for growth into the global clinical trials sector.

“We see Agilex as a natural fit into our existing pathology business and a logical entry point to the fast-growing global bioanalytical laboratory services market," said Healius’ chief executive officer Malcolm Parmenter.

“With all its scientists and staff joining us today, I extend a warm welcome to Agilex as it becomes an integral part of Healius pathology and of our future growth plan." 

Shares in Healius (ASX:HLS) are trading 0.3 per cent higher at $4.46. 

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.